AOP Health’s Rapiblyk® (landiolol) Now Accessible via Vizient® Contract
AOP Health US, LLC announced today that Rapiblyk® (landiolol) is now more widely available across the United States through contract with Vizient®, the nation’s largest provider-driven healthcare performance improvement company. Hospitals and health systems nationwide now have increased access through the Vizient catalog to Rapiblyk®, enhancing flexibility while expanding the availability of this critical care therapy. Furthermore, through the Vizient contract, participating hospital clients may have enhanced access to tiered pricing and streamlined ordering.
This represents an important milestone in ensuring that Rapiblyk availability is secured nationwide, supporting clinicians and healthcare providers in critical care environments,” said John Kimmet, General Manager of AOP Health US. “We’re reinforcing our commitment to making Rapiblyk accessible where it’s needed most.
AOP Health US previously announced the U.S. commercial availability of Rapiblyk® (landiolol), an ultra-short-acting, selective beta-1 adrenergic receptor blocker approved by the U.S. Food and Drug Administration (FDA) for the short-term reduction of ventricular rate in adults with supraventricular tachycardia (SVT) or irregular rapid heart rate, including atrial fibrillation and atrial flutter, in critical care settings
About Rapiblyk®
Rapiblyk® (landiolol) is an ultra-short-acting, selective beta-1 adrenergic receptor blocker indicated for the short-term reduction of ventricular rate in adults with supraventricular tachycardia (SVT) or irregular rapid heart rate, including atrial fibrillation and atrial flutter, especially in perioperative, postoperative, or critical-care settings. Rapiblyk® provides rapid onset and offset of action, allowing clinicians to achieve precise, controlled rate management with a favorable hemodynamic profile.
About AOP Health
AOP Health is a global enterprise with roots in Austria and a mission to address unmet medical needs through innovative, science-driven therapies in cardiovascular and rare disease. Since 1996, the AOP Health Group has been recognized as a pioneer in developing integrated therapy solutions that combine deep scientific expertise with a strong commitment to patient and physician needs.
Source link: https://www.businesswire.com/
